Dea Belazi, PharmD, MPh

Although payers have become somewhat accustomed to the high cost of specialty drugs, the price tags for gene therapies are causing “sticker shock.”

New drugs, virtual care, and a patient-focused approach are key during this period of transformation.

A patient’s ability to pay for specialty medications will continue to be an issue because drug costs are prohibitive and add barriers to accessibility.

As some of the nation’s leading pharmaceutical and biotech giants ramp up product development and commercialization, what was once a futuristic concept has become a reality.

A proactive approach can ensure that the patient is getting the right therapy at the right time and the right treatment plan with the least amount of waste.